JPRN-UMIN000011491已完成未知
Multi-institution study on efficacy and safety of Propiverine Hydrochloride for female patients with urge and stress urinary incontinence - Female patients with uRgE and Stress urinary incontinence study of Propiverine Hydrochloride (FRESH)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients with organ disease such as bladder stones, bladder tumors and urethral stricture in the lower urinary tract 2)Patients with bacterial infections (i.e. bacterial cystitis) or nonbacterial infections (i.e. interstitial cystitis) 3)Patients with advanced lower urinary tract obstruction or urinary retention 4)Patients without urinary sensation 5)Patients with overflow incontinence 6)Patients with history or complications of pelvic organ prolapse 7)Patients with pyloric, duodenal or intestinal obstruction 8)Patients with gastric or intestinal atony 9)Patients with angle-closure glaucoma 10)Patients with myasthenia gravis 11)Patients with severe heart disease 12)Patients with severe constipation 13)Patients with dementia, who are not able to complete the questionnaires 14)Patients with history of allergic reaction to Propiverine Hydrochloride or other similar medicine 15)Patients with history of surgery that affect urination such as TOT or TVT 16) Women who are pregnant, lactating, potentially pregnant or willing to get pregnant 17)Patients with previous surgery of the abdomen and pelvis or radiation within 6 months 18)Patients who started pelvic floor muscle exercise within 3 months 19)Patients who took Propiverine Hydrochloride or other similar medicine within 2 weeks before entry 20)Judged as being unsuitable for the trial by physician.
研究者
相似试验
进行中（未招募）
不适用
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)EUCTR2006-006522-25-BECSL Behring AG28
进行中（未招募）
不适用
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencyEUCTR2006-006522-25-DECSL Behring AG28
进行中（未招募）
1 期
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencyEUCTR2006-006522-25-GRCSL Behring AG18
进行中（未招募）
1 期
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)EUCTR2006-006522-25-GBCSL Behring AG18
进行中（未招募）
不适用
A Multicenter study on the efficacy and safety of Vivaglobin in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID) - NDPatients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 years.MedDRA version: 6.1Level: PTClassification code 10057863EUCTR2006-006522-25-ITCSL Behring AG28